Condition: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma · Sponsor: Akeso
This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.
This description comes directly from the study's public registry record.
Zhifang Yao, MD · 86-0760-89873999 · clinicaltrials@akesobio.com
Jiafu Ji, MD · jijiafu@hsc.pku.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Provincial Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Tianjin Provincial Tumor Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07023315